Evangelos S. Gragoudas, M.D.
Charles Edward Whitten Professor of Ophthalmology, Department of Ophthalmology
Director, Retina Service
Co-Director, Laser Laboratory
Co-Director, Retina Research Institute
Co-Director, Angiogenesis Laboratory
Dr. Gragoudas played a pivotal role in the development of proton bean therapy (PBT) for uveal melanoma, and performed both preclinical studies and the first clinical studies in patients. He continues to refine PBT and has taken a multidisciplinary approach to developing new strategies for managing uveal melanoma.Studies initiated in the early 1990s with Dr. Joan Miller produced a breakthrough for patients with wetAMD: photodynamictherapy (PDT) with verteporlin (VISudyne®). He and his colleagues identified the important role of vascular endothelial growth factor (VEGF) in ocular neovascularization, which formed the scientific basis for the present antiangiogenic treatments for neovascular AMD and other intraocular vascular diseases.